Nachrichten und Videos - IDORSIA N

Idorsia's once-daily TRYVIO™ (aprocitentan) is now available in the U.S., advancing treatment options for millions of patients with difficult-to-control hypertension PR Newswire RADNOR, Pa., Nov. 15, 2024 Once-daily TRYVIO, now available to prescribe in the U.S., is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other medications. TRYVIO is the first-and-only dual...

Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline PR Newswire PITTSBURGH, March 27, 2024 PITTSBURGH , March 27, 2024 /PRNewswire/ -- At a meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will outline how it is continuing to evolve its R&D strategy to deliver on its goal of building a more durable, higher-margin portfolio of patented innovation on the...

US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives PR Newswire RADNOR, Pa., March 20, 2024 Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately...

Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod. Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone payments, additional sales milestone payments and tiered royalties on annual net sales. Viatris and Idorsia will both contribute to the development costs for both programs. Includes future optionality to expand...

Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration PR Newswire PITTSBURGH, Feb. 28, 2024 Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue Potential Includes Future Optionality to Expand Collaboration With Additional Innovative Assets Combines Viatris' Financial Strength and Worldwide Operational Infrastructure With Idorsia's Proven, Highly Productive Drug...

Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “ Effects of aprocitentan on blood pressure lowering and proteinuria in patients with chronic kidney disease and resistant hypertension ” by George Bakris, MD, at the American Society of Nephrology (ASN)...

Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS PR Newswire ALLSCHWIL, Switzerland and RADNOR, Pa., July 10, 2023 The approximately 20 million US lives covered by CVS will now have easier and more affordable access to QUVIVIQ ALLSCHWIL, Switzerland and RADNOR, Pa. , July 10, 2023 /PRNewswire/ -- Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals US Inc. today announced that, effective immediately, CVS is covering QUVIVIQ ® (daridorexant) CIV on the...

Allschwil, Switzerland – June 2 6 , 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “Effects of the dual endothelin antagonist aprocitentan on ambulatory blood pressure indices in patients with resistant hypertension – results from the PRECISION study” by Prof. Markus Schlaich,...

Idorsia Pharmaceuticals Announces Support for a Clinical Trial being Conducted by the U.S. Department of Defense Evaluating QUVIVIQ (daridorexant) as Potential Therapy for Treatment of Posttraumatic Stress Disorder (PTSD) PR Newswire RADNOR, Pa., May 10, 2023 Further analysis may evaluate sleep parameters, providing additional information and data about QUVIVIQ in the PTSD population RADNOR, Pa. , May 10, 2023 /PRNewswire/ -- Idorsia Pharmaceuticals US Inc. announced today its support of a...

Idorsia Files Petition with the Drug Enforcement Administration (DEA) Urging Them to De-Schedule Dual Orexin Receptor Antagonist Class of Insomnia Medications PR Newswire RADNOR, Pa., April 4, 2023 RADNOR, Pa. , April 4, 2023 /PRNewswire/ -- Yesterday, a Citizen Petition (CP) was filed on behalf of Idorsia Pharmaceuticals (SIX: IDIA), urging the Drug Enforcement Administration (DEA) to de-schedule the dual orexin receptor antagonist (DORA) class of chronic insomnia medications based on a review...

Chronic insomnia disorder (CID) is a persistent medical condition that prevents sufferers from getting restorative sleep 1-3 ; research on wider societal and indirect economic costs associated with CID have been limited to date 1 New report indicates annual lost productivity costs of $417 billion in GDP across working age populations in the countries of focus * and annual “hidden” intangible wellbeing losses of $239.5 billion 1 Reducing the impact of CID could result in a boost to the GDP of...

Weitere Videos findet Ihr unter: https://www.deraktionaer.tv Idorsia hat vor kurzem Geschäftszahlen für das abgelaufene ......

The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated Allschwil, Switzerland – Dec ember 2 0 , 2022 Idorsia Ltd (SIX: IDIA) today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for aprocitentan, Idorsia’s investigational, novel dual endothelin receptor...

Daridorexant, taken every night for up to 12 months, was well-tolerated with no signs of tolerance (loss of effect) or physical dependence, and no evidence of withdrawal or rebound insomnia upon treatment discontinuation Exploratory efficacy endpoints show sustained improvements in nighttime sleep variables and daytime functioning Allschwil, Switzerland – December 1 2 , 2022 Idorsia Ltd (SIX: IDIA) today announced the publication of “ Long-term safety and tolerability of daridorexant in...

Simcere and Idorsia enter into a licensing agreement for daridorexant in China PR Newswire NANJING, China, Nov. 15, 2022 NANJING, China , Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere"), an innovation and R&D-driven pharmaceutical company,and Idorsia Ltd (SIX: IDIA, "Idorsia"), specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options, announced today that they have entered into an...

Idorsia Announces its Insomnia Medication, QUVIVIQ (daridorexant), is now Covered by TRICARE PR Newswire RADNOR, Pa., Nov. 10, 2022 The approximately 9.1 million US military service members and their families who are covered under TRICARE will now have easier and more affordable access to QUVIVIQ RADNOR, Pa. , Nov. 10, 2022 /PRNewswire/ -- Idorsia Pharmaceuticals US Inc. today announced that TRICARE, the healthcare program for active and retired US military personnel and their families, has...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 26 , 202 2 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2022. Commercial highlights QUVIVIQ ™ ( daridorexant ) was launched in the US in May 2022 and is building positive early momentum in the insomnia market. Net sales in the first half of 2022 were CHF 0.4 million PIVLAZ™ (clazosentan) was launched in Japan in April 2022 with strong support from neurosurgeons treating aSAH...

Ad hoc announcement pursuant to Art. 53 LR Aprocitentan reduces blood pressure compared to placebo by week 4 of treatment, the effect is maintained and confirmed over a period of 48 weeks, and is generally well tolerated with no major safety concerns Primary and key secondary endpoints were met with statistical significance and clinically meaningful results – the effect was consistent across multiple endpoints and methodologies of blood pressure monitoring Idorsia to host an investor webcast...

Idorsia's new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia PR Newswire ALLSCHWIL, Switzerland and RADNOR, Pa., May 2, 2022 In the US, QUVIVIQ™ (daridorexant) CIV 25 mg and 50 mg tablets are indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance 1 QUVIVIQ becomes Idorsia's first commercial product in the US, now available to help American adults who suffer from insomnia...

In Japan, PIVLAZ™ (clazosentan) 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing. With the positive listing decision, Japan’s National Health Insurance system has recognized that the clinical efficacy demonstrated with PIVLAZ fulfills an important medical need for patients. PIVLAZ is now available to physicians to start treating patients in Japan....